Analysis of the roles of anamorsin, anti-apoptotic molecule, onsurvival and proliferation of B lymphocytes

• Project/Area Number: 22591034
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Hematology
• Research Institution: Osaka University
• Principal Investigator: SHIBAYAMA Hirohiko 大阪大学, 医学系研究科, 講師 (60346202)
• Co-Investigator(Kenkyū-buntansha): KANAKURA Yuzuru 大阪大学, 医学系研究科, 教授 (20177489) ; TANAKA Hirokazu 大阪大学, 医学系研究科, 助教 (40360846)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: アナモルシン / Picot / 鉄・硫黄クラスター / B リンパ球 / 遺伝子改変マウス / LPS / ERK1/2 / IkB / Bリンパ球 / PICOT / PKC / p38MAPK / P38MAPK

Research Abstract

The proliferation of B lymphocytes (B) from anamorsin (AM) transgenic (Tg) mice by LPS was impaired compared with WT B. The Western blotting analysis showed the phosphorylation of ERK1/2 and IkB were reduced. Furthermore, the expression of IL-1β mRNA was decreased in AM Tg B by DNA array compared with WT B. From these data, it was clarified that AM overexpression had negative effects on LPS-induced signal pathways of B.

Research Products

• [Journal Article] Caspase-3-mediated cleavage of PICOT in apoptosis (2013)
  • Author(s): Yun N, Kim C, Cha H, Park WJ, ShibayamaH, Park I-S, Oh YJ
  • Journal Title: Biochem Biophys Res Commun Volume: 432 Pages: 533-538
  • Peer Reviewed
• [Journal Article] Caspase-3-mediated cleavage of PICOT in apoptosis. (2013)
  • Author(s): N Yun
  • Journal Title: Biochem Biophys Res Commun Volume: 432 Issue: 3 Pages: 533-538
  • DOI: 10.1016/j.bbrc.2013.02.017
  • Peer Reviewed
• [Journal Article] Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study (2012)
  • Author(s): Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F
  • Journal Title: Leuk Res Volume: 36 Pages: 1229-1236
  • Peer Reviewed
• [Journal Article] The endothelial antigen ESAM monitors hematopoietic stem cell status between quiescence and self-renewal (2012)
  • Author(s): Sudo T, Yokota T, Oritani K, Satoh Y, Sugiyama T, Ishida T, Shibayama H, Ezoe S, Fujita N, Tanaka H, Maeda T, Nagasawa T, Kanakura Y.
  • Journal Title: J Immunol Volume: 189 Pages: 200-210
  • Peer Reviewed
• [Journal Article] Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era (2012)
  • Author(s): Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Oshima R, Hatta Y, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Ish
  • Journal Title: Cancer Sci Volume: 103 Pages: 245-251
  • Peer Reviewed
• [Journal Article] The Endothelial Antigen ESAM Monitors Hematopoietic Stem Cell Status between Quiescence and Self-Renewal. (2012)
  • Author(s): Sudo, T.
  • Journal Title: J. Immunol. Volume: 189 Issue: 1 Pages: 200-210
  • DOI: 10.4049/jimmunol.1200056
  • Peer Reviewed
• [Journal Article] Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. (2012)
  • Author(s): N Tomita
  • Journal Title: Cancer Sci Volume: 103 Issue: 2 Pages: 245-251
  • DOI: 10.1111/j.1349-7006.2011.02139.x
  • Peer Reviewed
• [Journal Article] Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. (2012)
  • Author(s): K Ogata
  • Journal Title: Leuk Res Volume: 36 Issue: 10 Pages: 1229-1236
  • DOI: 10.1016/j.leukres.2012.05.006
  • Peer Reviewed
• [Journal Article] C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells (2012)
  • Author(s): Satoh Y, Mizuki M, Kanakura Y, et al
  • Journal Title: Leukemia Volume: 26(2) Issue: 2 Pages: 303-311
  • DOI: 10.1038/leu.2011.202
  • Peer Reviewed
• [Journal Article] Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma (2011)
  • Author(s): Zaki M, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Morii E, Aozasa K
  • Journal Title: Virchows Archiv Volume: 459 Pages: 361-366
  • Peer Reviewed
• [Journal Article] for the Japanese AMN107/2303 Study Group. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloidleukemia in chronic phase: results from the Japanese subgroup of ENESTnd (2011)
  • Author(s): Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda M, Matsuda A, Amagasaki T, Yanada M
  • Journal Title: Int J Hematol Volume: 93 Pages: 624-632
  • Peer Reviewed
• [Journal Article] PICOT is a molecule which binds to anamorsin. (2011)
  • Author(s): Saito Y, Shibayama H, Tanaka H, Tanimura A, Matsumura I, Kanakura Y.
  • Journal Title: Biochem Biophys Res Commun Volume: 408 Pages: 329-333
  • Peer Reviewed
• [Journal Article] A cell-death-defying factor, anamorsin mediates cell growth through inactivation of PKC and p38MAPK (2011)
  • Author(s): Saito Y, Shibayama H, Tanaka H, Tanimura A, Kanakura Y.
  • Journal Title: Biochem Biophys Res Commun Volume: 405 Pages: 303-307
  • Peer Reviewed
• [Journal Article] Oh YJ. Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain (2011)
  • Author(s): Park KA, Yun N, Shin DI, Choi SY, Kim H, Kim WK, Kanakura Y, Shibayama H
  • Journal Title: J Neural Transm Volume: 118 Pages: 433-444
  • Peer Reviewed
• [Journal Article] PICOT is a molecule which binds to anamorsin (2011)
  • Author(s): Saito Y, Shibayama H, Tanaka H, Tanimura A, et al
  • Journal Title: Biochem Biophys Res Commun Volume: 408 Pages: 329-333
  • Peer Reviewed
• [Journal Article] Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase : results from the Japanese subgroup of ENESTnd (2011)
  • Author(s): Nakamae H, Shibayama H, Kurokawa M, Fukuda T, et al
  • Journal Title: Int J Hematol Volume: 93 Pages: 624-632
  • NAID: 10029535125
  • Peer Reviewed
• [Journal Article] A cell-death-defying factor, anamorsin mediates cell growth through inactivation of PKC and p38MAPK. (2011)
  • Author(s): Saito Y, Shibayama H, et al.
  • Journal Title: Biochem Biophys Res Commun Volume: 405 Pages: 303-307
  • Peer Reviewed
• [Journal Article] Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain. (2011)
  • Author(s): Park KA, Shibayama H, et al.
  • Journal Title: J Neural Transm Volume: (印刷中)
  • Peer Reviewed
• [Journal Article] Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse (2010)
  • Author(s): Kurosawa S, Yamaguchi T, Miyawaki S, Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y, Shibayama H, Nakamae H, Mawatari M, Hatanaka K,Sunami K, Shimoyama M, Fujishima N, Maeda Y, Miura I, Takaue Y, Fukuda T
  • Journal Title: Haematologica Volume: 95 Pages: 1857-1864
  • Peer Reviewed
• [Journal Article] Peripheral T-cell lymphoma of Lennert type complicated by monoclonal proliferation of large B-cells (2010)
  • Author(s): Chihara T, Wada N, Kohara M, Matsui T, Masaya H, Maeda T, Shibayama H, Kanakura Y, Tani M, Morii E, Aozasa K.
  • Journal Title: Pathol Res Pract Volume: 206 Pages: 185-190
  • Peer Reviewed
• [Presentation] An anti-apoptotic molecule, Anamorsin, is essential for erythropoiesis through the regulation of cellular labile iron pool (2012)
  • Author(s): Tanimura A, Hamanaka Y, Fujita N, Doi Y, Ishibashi T, Sudo T, Matsui K, Ichii M, Saitoh N, Satoh Y, Ezoe S, Yokota T, Oritani K, Shibayama H, Kanakura Y
  • Organizer: The American Society of Hematology 54th Annual Meeting
  • Place of Presentation: Atlanta, USA
  • Year and Date: 2012-12-10
• [Presentation] Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2012)
  • Author(s): Hochhaus A, Ossenkoppele G, Reiffers J, Yao M, Shibayama H, Gattermann N, Hughes TP, Saglio G, Larson RA, Hoenekopp A, Gallagher NJ, Yu R, Blakesley RE, Lobo C, Kantarjian HM
  • Organizer: Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. The American Society of Hematology 53rd Annual meeting
  • Place of Presentation: San Diego, USA
  • Year and Date: 2012-12-10
• [Presentation] An anti-apoptotic molecule, Anamorsin, functions in both Fe/S cluster assembly and iron homeostasis (2012)
  • Author(s): Tanimura A, Hamanaka Y, Tanaka H, Matsumura I, Ishibashi T, Sudo T, Satoh Y, Yokota T, Ezoe S, Oritani K, Shibayama H, Kanakura Y
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-20
• [Presentation] Detection of change in LIC by MRI in a transfusion dependent MDS patient treated with deferasirox (2012)
  • Author(s): Hamanaka Y, Shibayama H, Tanimura A, Oritani K, Kanakura Y
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-20
• [Presentation] Evaluation of efficacy and safety of Bendamustine (B) treatment in Osaka Lymphoma Study Group (OLSG) (2012)
  • Author(s): Kohara T, Shibayama H, Uoshima N, Terada Y, Yoshida H, Masaie H, Ishikawa J, Mugitani A, Kumura T, Okamoto S, Kamitsuji Y, Sugahara H, Nakagawa M, Kawakami M, Ishiko J, Take H, Kosugi S, Nakata S, Nagate Y, Kida T, Tominaga N, Morita T, Inoue S, Yamada M
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
  • Year and Date: 2012-10-19
• [Presentation] An anti-apoptotic molecule, Anamorsin, functions in both iron-sulfur protein assembly and cellular iron homeostasis (2011)
  • Author(s): Tanimura A, Kondo Y, Tanaka H, Matsumura I, Ishibashi T, Sudo T, Satoh Y, Yokota T, Ezoe S, Oritani K, Shibayama H, Kanakura Y.
  • Organizer: The American Society of Hematology 53rd Annual meeting
  • Place of Presentation: San Diego, USA
  • Year and Date: 2011-12-10
• [Presentation] An anti-apoptotic molecule, Anamorsin, functions in both iron-sul fur protein assembly and cellular iron homeostasis (2011)
  • Author(s): Tanimura A, Kondo Y, Oritani K, Shibayama H, Kanakura Y, et al
  • Organizer: The American Society of Hematology 53rd Annual meeting
  • Place of Presentation: SanDiego Convention Center (USA)
  • Year and Date: 2011-12-10
• [Presentation] Results From the ENESTnd Extension Study : Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID (2011)
  • Author(s): Hochhaus A, Ossenkoppele G, Reiffers J, Yao M, Shibayama H, Gattermann N, et al
  • Organizer: The American Society of Hematology 53rd Annual meeting
  • Place of Presentation: SanDiego Convention Center (USA)
  • Year and Date: 2011-12-10
• [Presentation] OLSG 参加施設 . Clinical prognostic analysis of 465 follicular lymphoma (FL) cases from OLSG (Osaka Lymphoma Study Group) registry: OLSG cohort analysis (2011)
  • Author(s): 小原尚恵,柴山浩彦,武 弘典,魚嶋伸彦,服部英喜,畦西恭彦,菅原浩之,橋本光司,日野雅之,冨永信彦,青笹克之,金倉 譲
  • Organizer: 第73回日本血液学会
  • Place of Presentation: 愛知
  • Year and Date: 2011-10-14
• [Presentation] Nilotinib versus imatinib for newly-diagnosed CML-CP: ENESTnd 24-month update in Japanese patients. (2011)
  • Author(s): Nakaseko C, Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Kanda Y, Nagai T, Ohnishi K, Matsumura I, Matsuda A, Amagasaki T, Kojo N, Ito K.
  • Organizer: 第73回日本血液学会学術集会
  • Place of Presentation: 愛知
  • Year and Date: 2011-10-14
• [Presentation] Clinical prognostic analysis of 465 follicular lymphoma (FL) cases from OLSG (Osaka Lymphoma Study Group) registry : OLSG cohort analysis (2011)
  • Author(s): 小原尚恵, 柴山浩彦, ら
  • Organizer: 第73回日本血液学会学術集会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-14
• [Presentation] Nilotinib versus imatinib for newly-diagnosed CML-CP : ENESTnd 24-month update in Japanese patients (2011)
  • Author(s): Nakaseko C, Nakamae H, Shibayama H, et al
  • Organizer: 第73回日本血液学会学術集会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2011-10-14
• [Presentation] The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd : 24-month follow-up (2011)
  • Author(s): Saglio G, Kantarjian H, Reiffers J, Jootar S, Kalaycio ME, Shibayama H, et al
  • Organizer: American Society of Clinical Oncology 47th Annual Meeting
  • Place of Presentation: Mccormick place, Chicago (USA)
  • Year and Date: 2011-06-03
• [Presentation] A cell-death-defying factor, anamorsin, contributes cell growth through binding with PICOT and inactivation of PKCs and p38MAPK (2010)
  • Author(s): Shibayama H, Saito Y, Tanimura A, Tanaka H, Matsumura I, Kanakura Y
  • Organizer: The American Society of Hematology 52nd Annual meeting
  • Place of Presentation: Orlando, USA
  • Year and Date: 2010-12-04
• [Presentation] A Cell-Death-Defying Factor, Anamorsin, Contributes Cell Growth through Binding with PICOT and Inactivation of PKCs and p38MAPK. (2010)
  • Author(s): Shibayama H, Saito Y, et al.
  • Organizer: The American Society of Hematology 52nd Annual meeting
  • Place of Presentation: Orange County Convention Center, Orlando (USA)
  • Year and Date: 2010-12-04
• [Presentation] Efficacy and safety of nilotinib versus imatinib in Japanese patients with newly diagnosed CML-CP (2010)
  • Author(s): Shibayama H, Nakamae H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Ohnishi K, Matsuda A, Nagai T, Maeda Y, Amagasaki T, Kawahara E, Yanada M
  • Organizer: 第72回日本血液学会学術集会
  • Place of Presentation: 横浜
  • Year and Date: 2010-09-24
• [Presentation] Anti-apoptotic molecule Anamorsin is crucial for stromal function to support embryonic hematopoiesis (2010)
  • Author(s): Tanimura A, Tanaka H, Saito Y, Shibayama H, Matsumura I, Kanakura Y
  • Organizer: 第72回日本血液学会学術集会
  • Place of Presentation: 横浜
  • Year and Date: 2010-09-24
• [Presentation] A cell-death-defying factor, anamorsin, yields cell growth through inactivation of p38MAPK(抗細胞死分子アナモルシンは、p38MAPK を不活化し細胞増殖をもたらす) (2010)
  • Author(s): 齋藤有里, 柴山浩彦, 田中宏和, 谷村朗 , 松村 到 , 金倉 譲
  • Organizer: 第69回日本癌学会学術総会
  • Place of Presentation: 大阪
  • Year and Date: 2010-09-22
• [Presentation] 抗細胞死分子アナモルシンは、p38MAPKを不活化し細胞増殖をもたらす (2010)
  • Author(s): 齋藤有里、柴山浩彦, ら
  • Organizer: 第69回日本癌学会学術総会
  • Place of Presentation: 大阪国際会議場(大阪)
  • Year and Date: 2010-09-22
• [Presentation] A CELL-DEATH-DEFYING FACTOR, ANAMORSIN, CONTRIBUTES CELL GROWTH THROUGH INACTIVATION OF P38 MAPK (2010)
  • Author(s): Saito Y, Shibayama H, et al.
  • Organizer: The 15th Congress of European Hematology Association
  • Place of Presentation: The Gran Via Conference Center, Barcelona (Spain)
  • Year and Date: 2010-06-11
• [Presentation] Essential role of an anti-apoptotic molecule Anamorsin for both intrinsic and extrinsic regulation of murine fetal liver hematopoiesis (2010)
  • Author(s): Tanimura A, Tanaka H, Saito Y, Shibayama H, Matsumura I, Kanakura Y
  • Organizer: 15th Congress of the European Hematology Association
  • Place of Presentation: Barcelona, Spain
  • Year and Date: 2010-06-10
• [Presentation] cell-death-defying factor, anamorsin contributes cell growth throughinactivation of p38MAPK. (2010)
  • Author(s): Saito Y, Shibayama H, Tanaka H, Tanimura A, Matsumura I, Kanakura Y.
  • Organizer: 15th Congress of the European Hematology Association
  • Place of Presentation: Barcelona, Spain
  • Year and Date: 2010-06-10
• [Presentation] An anti-apoptotic molecule, Anamorsin, is essential for erythropoiesis through the regulation of cellular labile iron pool
  • Author(s): A Tanimura
  • Organizer: The American Society of Hematology 54th Annual Meeting
  • Place of Presentation: Atlanta, USA
• [Presentation] Short cycle of immunochemotherapy followed by radiation therapy compared with prolonged cycles of immunochemotherapy for localized DLBCL: The Osaka Lymphoma Study Group (OLSG) retrospective analysis
  • Author(s): Y Terada
  • Organizer: The American Society of Hematology 54th Annual Meeting
  • Place of Presentation: Atlanta, USA
• [Presentation] A rare genetic polymorphism in C5 confers poor response to the anti-C5 monoclonal antibody eculizumab by nine Japanese patients with PNH
  • Author(s): J Nishimura
  • Organizer: The American Society of Hematology 54th Annual Meeting
  • Place of Presentation: Atlanta, USA
• [Presentation] An anti-apoptotic molecule, Anamorsin, functions in both Fe/S cluster assembly and iron homeostasis
  • Author(s): A Tanimura
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
• [Presentation] Detection of change in LIC by MRI in a transfusion dependent MDS patient treated with deferasirox
  • Author(s): Y Hamanaka
  • Organizer: 第74回日本血液学会学術集会
  • Place of Presentation: 京都
• [Book] 造血器腫瘍学 (2012)
  • Author(s): 金倉譲
  • Total Pages: 776
  • Publisher: 日本臨床社
• [Book] がんの新しいバイオマーカー/予測因子による個別化医療時代に求められる抗がん剤開発 (2011)
  • Author(s): 柴山浩彦
  • Publisher: 技術情報協会
• [Remarks] 大阪大学大学院 医学系研究科 血液・腫瘍内科学ホームページアドレス:
  • URL: http://www.hematology.pro
• [Remarks] 大阪大学大学院医学系研究科 血液・腫瘍内科学教室ホームページ
• [Remarks]